welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Treatment Effect of Tamoxifen on Patients With DMD
study id #: NCT02835079
condition: Duchenne Muscular Dystrophy
status: active, not recruitingpurpose:
Duchenne muscular dystrophy (DMD) is a progressive devastating disease that affects mainly boys, with an incidence of about 1:3,500 live births. The pathology of DMD is a result of non-repaired muscle damage that leads to muscle-tissue replacement by scar tissue, a process known as fibrosis. Currently, there is no effective treatment for the disease. The only therapy offered to these boys are steroids which slightly delayed the disease progression. The boys lose their ability to walk at around the age of 12, and die in the 4th decade of life from severe heart and lung problems. In this study investigators will test the efficacy of Tamoxifen treatment in ambulatory DMD boys. Tamoxifen is a drug used for palliative treatment of breast cancer patients and has an outstanding safety profile. In addition, Tamoxifen was tested in the past in boys, for other pediatric indications, and showed an excellent safety with no side effects. Tamoxifen is being tested in this study, as a therapy for DMD, for the following reasons: (i) it was shown to have anti-fibrotic effect in multiple in-vivo systems; (ii) it assists in the repair of damaged muscles. In other words, Tamoxifen is expected to have a synergistic effect on DMD patients, due to its dual mechanism of action. Indeed, Tamoxifen was shown to have significant beneficial effects in the mdx mouse model of DMD. Also, a small compassionate cohort of 3 boys, treated for 6 months with Tamoxifen, yielded very encouraging results.
mechanism of action: Estrogen receptor antagonist to improve muslce strength
last updated: November 22, 2018
start date: November 2016
estimated completion: November 2020
phase of development: Phase 1
size / enrollment: 19
- 6-minute walk distance (6MWD) [Time Frame: The six minute walk distance will be tested during the 36 months of the trial. For the first 12 months, the 6 minute walk test will be tested every 3 months and for the follow up period of 24 months, will be done every 6 months.]
- North Star assessment (NSAA) [Time Frame: The NSAA will be tested during the 36 months of the trial. For the first 12 months, the NSAA will be tested every 3 months and for the follow up period of 24 months, will be done every 6 months.]
inclusion criteria: Ambulatory
exclusion criteria: Non-Ambulatory
Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyThe proposed clinical trial study of rAA...
Sodium Nitrate to Improve Blood FlowInvestigators recently showed that tadal...
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
Exploratory Study of NS-065/NCNP-01 in DMDThis study is designed to assess the saf...
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on CorticosteroidsThe purpose of the study is to assess th...
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body MyositisThe investigators are performing a gene ...
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular D...FibroGen, Inc., a leading biopharmaceu...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients With Duchenne Muscular Dystr...Capricor Therapeutics, Inc., a biotechno...
Mallinckrodt’s MNK-1411 gets orphan drug status for DMDMallinckrodt plc MNK announced that the ...